ArticleNature communications2017
Human CD26
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 103 citations in OpenAlex.
- Zbtb44-mediated transcriptional repression critically regulates colonic inflammation.Nature immunology · 2026Article
- C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Pharmacologic DPP-4 inhibition promotes CD8bioRxiv : the preprint server for biology · 2026Article
- C-terminus CD28 phosphorylation (Y218) modulates IL-2 secretion and antitumor effect of CAR-T cells.bioRxiv : the preprint server for biology · 2026Article
- The role of CD26 in breast cancer and its pan-cancer analysis.BMC cancer · 2026Article
- Review
- Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial.iScience · 2025Article
- Engineering resilient CAR T cells for immunosuppressive environment.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.Experimental hematology & oncology · 2025Review
- Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.Cancers · 2025Review
- A Novel Polymersome Nanocarrier Promotes Anti-Tumour Immunity by Improved Priming of CD8Immunology · 2025Article
- Deconvoluting TCR-dependent and -independent activation is vital for reliable Ag-specific CD4Science advances · 2025Article
- Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.International journal of molecular sciences · 2024Review
- CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase.International journal of molecular sciences · 2024Article
- Review
- Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy.Cancers · 2024Review
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- Comment on Lai et al. Dipeptidyl Peptidase 4 Stimulation Induces Adipogenesis-Related Gene Expression of Adipose Stromal Cells.International journal of molecular sciences · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Stefanie R BaileyDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA. flemins@musc.edu.
Michelle H NelsonDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID http://orcid.org/0000-0001-7597-0923
Kinga MajchrzakDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Jacob S BowersDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Megan M WyattDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID http://orcid.org/0000-0003-1316-260X
Aubrey S SmithDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Lillian R NealDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Keisuke ShiraiHematology/Oncology Division, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Carmine CarpenitoDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Cancer Center, Philadelphia, PA, 19104, USA.
Carl H JuneDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Cancer Center, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0003-0241-3557
Michael J ZillioxDepartment of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, 60153, USA.
Chrystal M PaulosDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA. paulos@musc.edu.
Medical University of South Carolina · USDartmouth College · USEli Lilly (United States) · USLoyola University Chicago · USUniversity of Pennsylvania · US
Funding
TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPYP01CA154778 · NCI · LOYOLA UNIVERSITY CHICAGO · PI NISHIMURA, MICHAEL I. · 2011 to 2015
$15.4MMechanisms of durable antitumor immunity via CD26hiCD4+ T cellsR01CA208514 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2016 to 2020
$1.7MCostimulatory mechanisms of antitumor Th17 cell immunityR01CA175061 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2013 to 2017
$1.5MDefining and translating the properties that sustain the antitumor efficacy of Th17 cellsF30CA200272 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BOWERS, JACOB S · 2015 to 2018
$182kElucidating the role of CD26 in T cell-mediated tumor immunityF31CA192787 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BAILEY, STEFANIE · 2015 to 2017
$131kNCI NIH HHS F30 CA200272NCI NIH HHS F31 CA192787NCI NIH HHS P01 CA154778NCI NIH HHS R01 CA175061NCI NIH HHS R01 CA208514
Abstract
CD8
Indexed as
Adoptive TransferAnimalsApoptosisbeta CateninCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell MovementCytokinesDipeptidyl Peptidase 4Disease Models, AnimalGranzymesHumansImmunityImmunologic MemoryImmunotherapyLymphoid Enhancer-Binding Factor 1BCL2 protein, humanbeta CateninCytokinesDipeptidyl Peptidase 4DPP4 protein, humanGranzymesGZMB protein, humanLEF1 protein, humanLymphoid Enhancer-Binding Factor 1Lysosomal-Associated Membrane Protein 1Proto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-kit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.